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There is accumulating evidence that inflamma-
tion plays a key role in the initiation and pro-
gression of cancer (Grivennikov et al., 2010). 
There are two types of inflammation that have 
opposing effects on tumors: (a) chronic inflam-
mation,  which  promotes  cancer  cell  survival 
and  metastasis  (Coussens  and  Werb,  2002; 
Condeelis and Pollard, 2006; Mantovani et al., 
2008), and (b) acute inflammation, which can 
trigger cancer cell destruction as illustrated by 
regressions  of  bladder  cancer  after  treatment 
with microbial preparations (Rakoff-Nahoum 
and  Medzhitov,  2009). Although  chronic  in-
flammation is often linked with the presence of 
type 2–polarized macrophages (M2), acute in-
flammation associated with cancer destruction 
is linked with type 1–polarized macrophages 
(M1). M1 macrophages are induced by the type 
1 cytokine IFN-, whereas, M2 macrophages 
are induced by the type 2 cytokines IL-4 and 
IL-13 (Mantovani and Sica, 2010).
Type 2 cytokines can contribute to tumori-
genesis in several ways. For example, IL-13 pro-
duced by NKT cells induces myeloid cells to 
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The human breast tumor microenvironment can display features of T helper type 2 (Th2) 
inflammation, and Th2 inflammation can promote tumor development. However, the  
molecular and cellular mechanisms contributing to Th2 inflammation in breast tumors 
remain unclear. Here, we show that human breast cancer cells produce thymic stromal 
lymphopoietin (TSLP). Breast tumor supernatants, in a TSLP-dependent manner, induce 
expression of OX40L on dendritic cells (DCs). OX40L+ DCs are found in primary breast 
tumor infiltrates. OX40L+ DCs drive development of inflammatory Th2 cells producing 
interleukin-13 and tumor necrosis factor in vitro. Antibodies neutralizing TSLP or OX40L 
inhibit breast tumor growth and interleukin-13 production in a xenograft model. Thus, 
breast cancer cell–derived TSLP contributes to the inflammatory Th2 microenvironment 
conducive to breast tumor development by inducing OX40L expression on DCs.
© 2011 Pedroza-Gonzalez et al.  This article is distributed under the terms of 
an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the 
first six months after the publication date (see http://www.rupress.org/terms).   
After six months it is available under a Creative Commons License (Attribution– 
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
commons.org/licenses/by-nc-sa/3.0/).
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>410,000 will die from the disease (Coughlin and Ekwueme, 
2009). Here, we show that inflammatory Th2 cells that promote 
tumor development are driven by breast cancer–derived TSLP, 
which induces and maintains OX40L-expressing DCs in the 
tumor microenvironment. Thus, TSLP, and down-stream mole-
cules, might represent novel potential therapeutic targets.
ReSuLTS
Inflammatory Th2 cells in primary breast cancer tumors
Our earlier study using a pilot cohort of 19 samples of pri-
mary breast cancer tumors revealed the secretion, upon acti-
vation with PMA and ionomycin, of both type 1 (IFN-) and 
type 2 (IL-4 and IL-13) cytokines (Aspord et al., 2007). The 
current study extends the analysis to a total of 99 consecutive 
samples (Table S1). Supernatants of activated tumor fragments 
display high levels of IFN-, IL-2, IL-4, IL-13, and TNF   
(Fig. 1 A and Table S1).  Supernatants from tumor sites 
contained significantly higher levels of IL-2, type 2 (IL-4 and 
IL-13), and inflammatory (TNF) cytokines than those from 
macroscopically uninvolved surrounding tissue (Fig. 1 B and 
Table S1). Whereas a significant correlation can be observed 
between IL-2 levels in tumor and adjacent tissue (P = 0.02), 
IL-4 and IL-13 levels are not correlated (P = 0.5), further 
suggesting polarization of cytokine environment in breast 
tumors (Fig. 1 B). IFN- did not correlate with other cyto-
kine levels (Table S1). However, levels of TNF were correlated 
with those of IL-13 (P < 0.0001; r = 0.62; n = 98) and IL-4 
(P = 0.0175; r = 0.31; n = 59; Fig. 1 C). Thus, this survey of 
cytokine expression suggested Th2 polarization in the breast 
tumor microenvironment.
To identify the cells producing these cytokines, single-cell 
suspensions were prepared from tumors; activated for 5 h with 
PMA and ionomycin; stained with antibodies against T cells 
and cytokines; and analyzed by flow cytometry. Gated viable 
CD4+CD3+ T cells expressed IL-13 (3.67%), most of them 
coexpressing IFN- and TNF (Fig. 1 D and Fig. S1 A).   
A small fraction of IL-13+CD4+ T cells coexpressed IL-4, but 
none expressed IL-10 (Fig. 1 D). Such T cells have been re-
ferred to as inflammatory Th2 cells that are involved in aller-
gic inflammatory diseases (Liu et al., 2007). Flow cytometry 
analysis of consecutive tumor infiltrates (n = 22) shows the 
overall increased percentages of IL-4– and IL-13–secreting 
CD4+CD3+ T cells (P = 0.0313 and P = 0.0156, respectively) 
when compared with adjacent tissue samples (Fig. 1 D and 
Fig. S1 B). Thus, the difference between tumor tissue and ad-
jacent tissue appears to be caused by both the increased num-
bers of infiltrating T cells and enhanced polarization. The 
analysis of frozen tissue sections further demonstrated that in-
filtrating T cells in primary breast cancer tumors express IL-13 
(Fig. 1 E). Thus, breast cancer tumors are infiltrated with in-
flammatory Th2 cells.
DCs infiltrating breast cancer tumors express OX40 ligand
Because OX40 ligation drives the differentiation of CD4+  
T cells into inflammatory Th2 (Ito et al., 2005), we analyzed 
the presence of OX40L in primary breast cancer tumors.   
make TGF-,  which  ultimately  inhibits  CTL  functions 
(Berzofsky and Terabe, 2008). Spontaneous autochthonous 
breast carcinomas arising in Her-2/neu transgenic mice ap-
pear more quickly when the mice are depleted of T cells, 
which is evidence of T cell–mediated immunosurveillance 
slowing  tumor  growth  (Park  et  al.,  2008). This  immuno-
surveillance could be further enhanced by blockade of IL-13, 
which slowed the appearance of these autologous tumors 
compared with control antibody-treated mice (Park et al., 
2008). A spontaneous mouse breast cancer model recently 
highlighted the role of Th2 cells which facilitate the develop-
ment  of  lung  metastasis  through  macrophage  activation 
(DeNardo et al., 2009). We identified CD4+ T cells secreting 
IFN-  and  IL-13  in  breast  cancer  tumors  (Aspord  et  al., 
2007). We also found that breast cancer cells express IL-13 on 
cell surface. Autocrine IL-13 has been shown to be important 
in  the  pathophysiology  of  Hodgkin’s  disease  (Kapp  et  al., 
1999; Skinnider et al., 2001, 2002). IL-13 and IL-13R are fre-
quently expressed by Hodgkin’s and Reed-Sternberg cells 
(Skinnider et al., 2001), and IL-13 stimulates their growth 
(Kapp et al., 1999; Trieu et al., 2004). Similar to Hodgkin’s 
cells  (Skinnider  et  al.,  2002),  breast  cancer  cells  express 
pSTAT6 (Aspord et al., 2007), suggesting that IL-13 actually 
delivers signals to cancer cells. However, the mechanisms un-
derlying the development of Th2 inflammation in breast can-
cer are unknown.
Like many other features of the immune response, Th1/
Th2 polarization is regulated by DCs. In the steady state, non-
activated (immature) DCs present self-antigens to T cells, 
which leads to tolerance (Hawiger et al., 2001; Steinman et al., 
2003). Once activated (mature), antigen-loaded DCs are 
geared toward the launching of antigen-specific immunity 
(Finkelman et al., 1996; Brimnes et al., 2003) leading to the 
proliferation of T cells and their differentiation into helper 
and effector cells. DCs are composed of distinct subsets, in-
cluding myeloid DCs (mDCs) and plasmacytoid DCs (Caux 
et al., 1997; Maldonado-López et al., 1999; Pulendran et al., 1999; 
Luft et al., 2002; Dudziak et al., 2007; Klechevsky et al., 
2008). DCs are also endowed with functional plasticity, i.e., 
they  respond  differentially  to  distinct  activation  signals 
(Steinman  and  Banchereau,  2007).  For  example,  IL-10– 
polarized mDCs generate anergic CD8+ T cells that are un-
able to lyse tumors (Steinbrink et al., 1999), as well as CD4+ 
T cells with regulatory/suppressor function (Levings et al., 
2005). In contrast, thymic stromal lymphopoietin (TSLP)– 
polarized mDCs are conditioned to express OX40 ligand 
(OX40L) and to expand T cells producing type 2 cytokines 
(Soumelis et al., 2002; Gilliet et al., 2003). Both the distinct DC 
subsets and their distinct response to microenvironment contrib-
ute to the generation of unique adaptive immune responses.
Unraveling the mechanisms by which breast cancer po-
larizes the immune responses might offer novel therapeutic 
options. This is important because despite declining mortality 
rates, breast cancer ranks second among cancer-related deaths 
in women. Worldwide, it is estimated that more than 1 million 
women  are  diagnosed  with  breast  cancer  every  year,  and JEM VOL. 208, March 14, 2011 
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mean ± SE for surrounding tissue = 1.5 ± 0.8% [n = 7] 
and for breast cancer tumors 11 ± 1.67% [n = 12], respec-
tively; Fig. 2 B). Thus, breast cancer tumors are infiltrated 
with OX40L+ mDCs.
Breast cancer tumors produce soluble factors that induce 
functional OX40L expression on DCs
To identify the breast cancer tumor factors that induce 
OX40L  on  mDCs,  LINnegHLA-DR+  CD123  CD11c+ 
mDCs were sorted from blood of healthy volunteers and   
Immunofluorescence staining of frozen tissue sections of pri-
mary breast cancer tumors showed the expression, in 57 out 
of 60 analyzed tumors, of OX40L by a majority of HLA-
DRhigh cells (Fig. 2 A). These OX40L+ cells are located in 
peritumoral areas (Fig. 2 A). Flow cytometry analysis of 
single-cell suspensions further confirmed the expression of 
OX40L by a fraction of HLA-DRhigh CD14neg CD11chigh 
mDCs (Fig. 2 B). Paired analysis demonstrated that the tumor 
beds express higher percentages of OX40L+ mDCs than 
the surrounding tissue (P = 0.0156; n = 7 paired samples; 
Figure 1.  Inflammatory Th2 in breast cancer immune environment. (A) Cytokine profiles as determined by Luminex in supernatants of human 
breast tumor fragments stimulated for 16 h with PMA and ionomycin. Numbers on the x-axis indicate the number of tissue samples from different pa-
tients tested. (B) Cytokine profiles as determined by Luminex in supernatants of tumor fragments (T) and surrounding tissue (ST) from the same patient 
after PMA and ionomycin stimulation. Cytokine concentration values of IL-2, IL-4, and IL-13 from T and ST samples were plotted and analyzed using lin-
ear regression to determine the level of correlation between cytokine concentration in T and ST samples. (C) Cytokine profiles as determined by Luminex 
in supernatants of tumor fragments after PMA and ionomycin stimulation. Cytokine concentration values of TNF and IL-13 and of TNF and IL-4 were 
plotted and analyzed using nonparametric Spearman correlation to determine the level of correlation of two cytokines concentration in tumor samples. 
(D, top) Single-cell suspensions from tumor samples were stimulated for 5 h with PMA and ionomycin. Cytokine production was measured by flow  
cytometry. Dot plots are gated on CD3+CD4+ T cells. (top right dot plot) Blue indicates gate on CD3+CD4+IL-13+ T cells that coexpress IFN- and TNF. Rep-
resentative of four different patients from whom we have been able to obtain sufficient numbers of cells for 10-color analysis (patient nos. 148, 155, 164, 
and 169). Bottom, percentages of CD4+ T cells expressing IL-4 and IL-13 in tumor infiltrates and surrounding tissue (ST) were analyzed by flow cytometry. 
Dotted lines indicate paired samples from the same patient (n = 7, Wilcoxon matched-pairs ranked test). Single points indicate the percentage of cytokine 
expressing cells in tumor samples analyzed by flow cytometry for which we did not obtain sufficient number of cells from surrounding tissue to allow the 
analysis. (E) Frozen tissue sections from the same patient as in D were analyzed by immunofluorescence. Triple staining with anti-CD3-FITC (green), anti–
IL-13–Texas red (red), and DAPI nuclear staining (blue). Bar, 90 µm.482 TSLP–OX40L–IL-13 axis in human breast cancer | Pedroza-Gonzalez et al.
To test whether primary breast cancer tumors could also 
regulate OX40L expression, fragments of primary tumors 
were sonicated, centrifuged, filtered, and used in cultures with 
blood mDCs. As illustrated in Fig. 2 D, mDCs acquired both 
CD83 (a DC maturation marker) and OX40L. To determine 
the impact of OX40L on the generation of inflammatory Th2 
responses in breast cancer, blood mDCs were first exposed for 
48 h to either TSLP or breast tumor–soluble fractions. Exposed 
mDCs were then used to stimulate naive allogeneic CD4+  
T cells with either the anti-OX40L antibody or a relevant 
exposed to breast cancer supernatants. These were generated 
from established breast cancer cell lines expanded in vitro 
(Hs578T,  MDA-MB-231,  MDA-MB-468,  MCF7,  HCC-
1806, and T47D; Table S2) and breast cancer tumors estab-
lished  in  vivo  by  implanting  breast  cancer  cell  lines  in 
immunodeficient mice (Aspord et al., 2007). As illustrated in 
Fig. 2 C, mDCs exposed for 48 h to Hs578T and HCC-1806 
supernatants expressed OX40L. Four of the five breast cancer 
cell  lines,  with  the  notable  exception  of T47D,  induced 
OX40L expression on mDCs (Fig. S1 C).
Figure 2.  OX40L in breast cancer immune environment. (A) Immunofluorescence of primary breast tumor with indicated antibodies. Bar, 180 µm. 
Representative of 57/60 tumors analyzed. (B) Flow cytometry analysis of single-cell suspensions of primary breast tumors and surrounding tissue. Dot 
plots are gated on CD14neg nonlymphocytes. OX40L expression is analyzed on HLA-DRhighCD11chigh DCs. Graph summarizes percentages of OX40L-expressing  
DCs in tumor infiltrates and surrounding tissue (ST) analyzed by flow cytometry. Dotted lines indicate paired samples from the same patient (Wilcoxon 
matched-pairs ranked test). Single points indicate the percentage of OX40L+ DCs in tumor samples for which we did not obtain sufficient number of cells 
from surrounding tissue to allow the analysis. (C and D) mDCs were exposed to media alone, to supernatant of breast cancer cell lines (1806 or Hs587T), 
or to sonicate of primary breast cancer tissue from patients (tumor 43). OX40L and CD83 were measured by flow cytometry. FMO, fluorescence minus one 
indicates controls where one staining fluorescence is omitted to set negative gate. (E and F) mDCs were exposed for 48 h to supernatants of breast cancer 
cells Hs578T, and then co-cultured with allogeneic naive CD4+ T cells in the presence of 40 µg/ml of anti-OX40L (Ik-5 clone) or isotype control antibody. 
After 1 wk, cells were collected and restimulated for 5 h with PMA/ionomycin for intracellular cytokine staining. Data in E are representative of four ex-
periments. (F) Summary of the effect of blocking OX40L during T cell stimulation by tumor-activated DCs. Graph shows the proportion of IL-13–secreting 
cells induced by DCs activated with supernatants from breast cancer cell line Hs578T (left) or primary breast tumors (right, T15, T29, and T53).JEM VOL. 208, March 14, 2011 
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and secreted TSLP (Fig. 3 A). Supernatants of some primary 
breast cancer tumors stimulated with PMA and ionomycin 
displayed up to 300 pg/ml TSLP (Fig. 3 B). The expression of 
TSLP by cancer cells was further analyzed using an anti-TSLP 
antibody and immunofluorescence of frozen breast cancer   
tumors generated in the xenograft model (Aspord et al., 2007). 
There, subcutaneous MDA-MB-231 tumors transplanted in 
mice expressed TSLP (Fig. 3 C). The specificity of the staining 
is demonstrated by pretreatment of the antibody with recom-
binant TSLP (Fig. S3).
Importantly, TSLP is expressed in 35 out of 38 analyzed 
primary breast cancer tumors obtained from patients regard-
less of grade, histology, or stage of analyzed tumors. Fig. 3 D 
illustrates the pattern of TSLP staining and coexpression with 
isotype control. Blocking OX40L prevented the expansion of 
IL13+CD4+ or TNF+CD4+ T cells by TSLP-primed mDCs 
(>50%  inhibition;  Fig.  S2 A),  mDCs  exposed  to  Hs578T 
breast cancer cells (n = 4; median inhibition of IL13+CD4+ 
cells = 74%; range = 67–80%; Fig. 2, E and F), and mDCs ex-
posed to sonicates of randomly selected primary breast cancer 
tumors (Fig. 2 F and Fig. S2 B). Thus, breast cancer cells pro-
duce factors that activate mDCs and induce them to express 
OX40L and to elicit inflammatory Th2 cells.
Breast cancer tumors express and secrete TSLP
OX40L can be induced on mDCs by TSLP, an IL-7–like cyto-
kine produced by epithelial cells (Liu et al., 2007; Ziegler 
and Artis, 2010). All tested breast cancer cell lines expressed 
Figure 3.  TSLP in breast cancer environment. (A) Luminex analysis of TSLP in supernatants of breast cancer cell lines after 24 h of culture in the 
presence of PMA and ionomycin. (B) Luminex analysis of TSLP levels in supernatants of primary breast tumors (from 44 patients) activated with PMA and 
ionomycin. (C) NOD/SCID/2m/ mice were irradiated the day before tumor implantation and 10 × 106 MDA-MB-231 cells were implanted by subcuta-
neous injection. Tumors were harvested at 4 wk after implant. Frozen tissue sections were analyzed by immunofluorescence for expression of TSLP (red). 
Actively dividing cells were identified by expression of Ki67 (green). Bar, 45 µm. (D and E) Frozen tissue sections from primary breast tumors from patients 
(38 patient samples) were analyzed by immunofluorescence for expression of TSLP. Tissues were also stained for the expression of IL-13 and cytokeratin 
19, as indicated, to confirm TSLP expression by cancer cells. Staining pattern is representative of 35 out of 38 analyzed tumor samples from different 
patients. Bars: (D) 180 µm; (E) 15 µm. (F) NOD/SCID/2m/ mice were sublethally irradiated and transplanted with human CD34+ HPCs by intravenous 
injection. 4 wk after HPC transplant, 5 × 106 MDA-MB-231 breast cancer cells were implanted subcutaneously. Tumors at the site of implantation, as well 
as lungs and kidneys, were harvested at 3 mo after implant. Frozen tissue sections were analyzed by immunofluorescence for expression of TSLP (green) 
and cytokeratin (red). Staining pattern is representative of tumors from three different mice. Bar, 90 µm.484 TSLP–OX40L–IL-13 axis in human breast cancer | Pedroza-Gonzalez et al.
is specific to epithelial cells as no staining can be found in   
tumor-infiltrating fibroblasts (Fig. S4 B). Furthermore, non-
malignant breast epithelia can also express TSLP (Fig. S4 C).
Thus, similar to normal skin or lung epithelium, breast 
epithelial cells and breast cancer cells have the capacity to ex-
press, produce, and secrete TSLP.
cytokeratin 19–positive cells. It demonstrates that TSLP is ex-
pressed in the cytoplasm and the nucleus of breast cancer cells 
that display IL-13 on their surface (Fig. 3 E). Importantly, 
TSLP is also expressed in lung and kidney metastasis of MDA-
MB-231 tumors in humanized mice (Fig. 3 F) and in breast can-
cer tumor metastasis from patients (Fig. S4 A). TSLP expression 
Figure 4.  Blocking TSLP in vitro. (A) mDCs were incubated with supernatant of breast cancer cell line Hs578T in the presence or absence of 20 µg/ml 
of anti-TSLP (AB 19024; rabbit IgG). OX40L expression was measured by flow cytometry after 48 h of incubation. (B) mDCs treated as in A were co- 
cultured with naive allogeneic CD4+ T cells for 7 d. IL-13 production was measured by intracellular cytokine staining and flow cytometry after cells were 
restimulated for 5 h with PMA and ionomycin. Data are representative of three experiments. (C) mDCs were incubated with soluble factors from sonicated 
human breast tumors (T53, T60, and T97) in the presence or absence of 20 µg/ml of anti-TSLP (AB 19024; rabbit IgG). OX40L expression was measured by 
flow cytometry after 48 h of incubation. (D) mDCs treated as in C were co-cultured with naive allogeneic CD4+ T cells for 7 d. IL-13 production was mea-
sured by intracellular cytokine staining and flow cytometry after cells were restimulated for 5 h with PMA and ionomycin. Representative of three pa-
tients tested. Blue dots represent IL-13+ T cells gated in the same sample. (E) Graph shows data from three independent experiments as described in A–D.JEM VOL. 208, March 14, 2011 
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whether this axis might actually contribute to breast cancer 
tumor development. To address this question, humanized mice 
were reconstituted with both Hs578T cells and T cells with 
or without anti-OX40L–, anti-TSLPR–, and anti-TSLP– 
neutralizing antibodies. As shown in Fig. 6 A, the administra-
tion of neutralizing anti-OX40L antibodies leads to significant 
inhibition of tumor development.
The administration of a neutralizing anti-TSLP antibody 
also results in the inhibition of tumor development (Fig. 6 B). 
TSLP blockade also leads to decreased secretion of IL-4 and 
IL-13 by tumor infiltrating T cells upon PMA and ionomycin 
activation (Fig. 6 C). Finally, the administration of antibody 
blocking TSLPR nearly completely blocks tumor develop-
ment driven by CD4+ T cells (Fig. 6 D). These results indicate 
that the TSLP contributes to breast cancer pathogenesis.
DISCuSSION
Here, we show that breast cancer is infiltrated with inflamma-
tory Th2 cells and that such T cells are driven by OX40L on 
DCs. Blocking OX40L in vitro prevents generation of these 
CD4+ T cells without impact on IL-10–producing CD4+  
T cells. Blocking OX40L in vivo partially prevents T cell– 
dependent acceleration of breast cancer tumor development. 
OX40L is not constitutively expressed, but can be induced on 
DCs, macrophages, and B cells; e.g., upon CD40 engagement 
or cytokine signals such as TSLP or IL-18, as well as upon 
TLR stimulation (Ito et al., 2005; Croft et al., 2009). Thus, the 
Anti-TSLP antibodies block the generation of inflammatory 
Th2 responses in vitro
To determine the impact of blocking TSLP on the generation 
of inflammatory Th2 responses in breast cancer, blood mDCs 
were first exposed for 48 h to either TSLP or breast tumor–
soluble fractions. Addition of anti-TSLP–neutralizing anti-
bodies to breast cancer tumor supernatants inhibited their 
ability to induce OX40L on mDCs (Fig. 4 A). Such mDCs 
displayed a diminished capacity to expand IL13+CD4+ or 
TNF+CD4+ T cells (n = 3; median inhibition = 73%, range = 
72–77%; Fig. 4, B and E). Likewise, adding anti-TSLP– 
neutralizing antibody to sonicate of randomly selected primary 
breast cancer tumors led to down-regulation of OX40L ex-
pression by mDCs (Fig. 4 C) and decreased expansion of 
IL13+TNF+CD4+ T cells (Fig. 4, D and E). Finally, when 
anti-TSLP receptor  chain (TSLPR) antibody was added to 
mDCs during their exposure to the supernatant of three dif-
ferent breast cancer cell lines (Hs578T, MDA-MB-231, and 
MCF7; Fig. 5 A), resulting mDCs showed a much diminished 
expansion of IL13+ CD4+ T cells (Fig. 5 B). Thus, TSLP is the 
factor secreted by breast cancer cells that contributes to gen-
eration of inflammatory Th2 responses.
Antibodies neutralizing TSLP–OX40L axis block tumor 
development in vivo
Our results thus far suggest a role for the TSLP–OX40L axis 
in generation of IL13+TNF+CD4+ T cells, but do not establish 
Figure 5.  Blocking TSLP-R in vitro. (A) mDCs were treated with anti-TSLP-R (clone AB81_85.1F11, mouse IgG1), media or control antibody during 
activation with TSLP or with supernatant of one of the three different breast cancer cell lines (Hs578T, MDA-MB-231, and MCF7). mDCs were then co-
cultured with allogeneic naive CD4+ T cells. After 1 wk, cells were collected, restimulated for 5 h with PMA and ionomycin, and analyzed by flow cytom-
etry. (B) Analysis of different experiments showing the effect of blocking TSLP-R on the induction of IL-13 secreting cells as described in A.486 TSLP–OX40L–IL-13 axis in human breast cancer | Pedroza-Gonzalez et al.
cells  markedly  in-
crease TSLP expres-
sion  (Liu  et  al., 
2007). The TSLP-
activated  DCs  mi-
grate to the draining lymph nodes, prime CD4+ T cells via 
OX40L  to  differentiate  into  inflammatory Th2  effector   
and memory cells, and thus initiate the adaptive phase of 
allergic immune responses. Interestingly, in breast cancer, 
OX40L+ mDCs are present in the tumor. It remains to be 
determined whether this reflects their inability to migrate 
from the tumor to draining lymph nodes. Indeed, such   
an evasion mechanism has been documented recently in   
human and mouse tumors showing an inhibition of DC 
migration from tumors to tumor-draining lymph nodes 
(Villablanca et al., 2010). This effect depends on tumor- 
derived ligands of the liver X receptors (Villablanca et al., 
2010). It also remains to be determined whether these DCs 
are able to prime Th2 immunity in situ in tertiary lymphoid 
structures or whether their main role is to maintain the ac-
tivation and survival of Th2 cells at the tumor site. Their 
ability to maintain Th2 cell phenotype and effector func-
tion is supported by our earlier studies showing that T cells 
isolated from experimental breast tumors and transferred to 
naive tumor-bearing humanized mice can promote tumor 
development even at low numbers and upon single injec-
tion (Aspord et al., 2007).
presence of OX40L+ mDCs in breast tumors indicate sus-
tained activation of DCs in tumor environment. Indeed, 
OX40L expression by DCs is driven by TSLP secreted from 
breast cancer cells. Accordingly, TSLP expression can be found 
in primary and metastatic tumors. Blocking TSLP reduces in-
flammation and partially inhibits tumor development.
Based on our results presented herein and in our earlier 
studies, we propose a vicious circle of smoldering type 2 in-
flammation that perpetuates breast cancer and which is main-
tained by TSLP. There, breast cancer attracts DCs, possibly 
through  macrophage  inflammatory  protein  3    (MIP3-; 
Bell et al., 1999). Tumor-infiltrating DCs are then exposed to 
TSLP secreted by breast cancer cells, which triggers their 
maturation and OX40L expression. This might explain the 
aseptic mDC maturation that we found in breast cancer (Bell 
et  al.,  1999; Aspord  et  al.,  2007).  OX40L+  mDCs  induce 
CD4+ T cells to secrete IL-13, as well as TNF. These inflam-
matory CD4+ T cells contribute to tumor development in an 
IL-13–dependent  pathway  (Aspord  et  al.,  2007). Thus  far, 
TSLP represents the only factor that activates mDCs without 
inducing them to produce Th1-polarizing cytokines (Liu   
et al., 2007). Under normal physiological conditions, TSLP 
appears to play a critical role in CD4+ T cell homeostasis in 
the peripheral mucosa-associated lymphoid tissues and in the 
positive selection and/or expansion of regulatory T (T reg) 
cells in the thymus (Watanabe et al., 2005a,b). In inflamma-
tory conditions such as atopic dermatitis and asthma, epithelial 
Figure 6.  Blocking OX40L-TSLP in vivo. 
(A) NOD/SCID/2m/ mice were sublethally 
irradiated and transplanted with human 
CD34+ HPCs by intravenous injection. 4 wk 
after HPC transplant, 10 × 106 Hs578T breast 
cancer cells were implanted subcutaneously. 
3, 6, and 9 d after, mice were reconstituted 
with autologous total T cells together with 
200 µg per injection of blocking anti-OX40L 
or isotype control antibody (mouse Ig; red 
arrows). PBS group was injected with tumor 
cells but not with T cells (gray line). Tumor 
size was measured at indicated times. Mean 
values from three experiments representing 
nine mice per each condition. Anti-OX40L and 
isotype-treated cohorts were compared sta-
tistically. (B) NOD/SCID/2m/ mice were 
irradiated and implanted with 10 × 106 
Hs578T breast cancer cells together with 200 µg 
per injection of neutralizing anti-TSLP  
(rabbit), rabbit isotype control antibody, or 
PBS. 3, 6, and 9 d after, mice were reconsti-
tuted with immature DCs and autologous 
total T cells together with 200 µg per injection 
of neutralizing anti-TSLP (rabbit), rabbit iso-
type control antibody or PBS. Representative 
of three independent experiments with a total 
of nine mice in TSLP blockade group. (C) Cyto-
kine secretion in single-cell suspensions from 
tumors after 16-h restimulation with PMA 
and ionomycin. (D) Same as in B, but mice 
were injected with anti-TSLPR or isotype con-
trol at days 3, 6, and 9. Representative of two 
independent experiments. n indicates number 
of mice per cohort in this representative 
experiment.JEM VOL. 208, March 14, 2011 
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Interestingly, studies in mice suggest the role of Th2 cyto-
kines in mammary gland development. Indeed, the differenti-
ation of the luminal epithelial lineage appears to require 
autocrine signaling by Th2 cytokines, as shown by reduced 
differentiation and alveolar morphogenesis in both Stat6 and 
IL-4–/IL-13–deficient mice during pregnancy (Khaled et al., 
2007). Yet, in the murine model of endogenous breast cancer 
type 2, polarized CD4+ T cells are essential to the metastatic 
process via secretion of IL-4, which induces macrophages to 
secrete epidermal growth factor (DeNardo et al., 2009). Simi-
lar to endogenous mouse model, in our model of transplanted 
metastatic human breast cancer IL-13 is derived from micro-
environment. IL-13 can exert pro-cancer activity in several 
ways, including the triggering of TGF- secretion (Terabe   
et al., 2000, 2003; Park et al., 2005; Shimamura et al., 2010). 
Furthermore, IL-4 exposure of cancer cells leads to the up-
regulation of antiapoptotic pathways via mobilization of 
STAT6 (Zhang et al., 2008). We have shown that STAT6 is 
phosphorylated in primary breast cancer tumors (Aspord et al., 
2007). All these antiapoptotic pathways are likely to synergize 
to promote the survival of cancer cells and facilitate metastasis. 
Importantly, such a protective effect on cancer cell suscepti-
bility to apoptosis might increase their resistance to chemother-
apy (Todaro et al., 2008) and immune-mediated cytotoxicity 
driven by Granzyme B (Sarin et al., 1997; Heibein et al., 
2000). Thus, the TSLP–OX40L–IL13 axis might offer a novel 
therapeutic target.
MATeRIALS AND MeTHODS
Isolation and culture of myeloid dendritic cells. DCs were purified 
from buffy coat of blood from healthy donors. In brief, DCs were enriched 
from mononuclear cells by negative selection using a mixture of antibodies 
against linage markers for CD3, CD14, CD16, CD19, CD56, and glycopho-
rin A (Dynabeads Human DC Enrichment kit; Invitrogen). Cells from nega-
tive fraction were immunolabeled with anti–human FITC-labeled lienage 
cocktail (CD3, CD14, CD16, CD19, CD20, and CD56; BD); PE-labeled 
CD123 (mIgG1; clone 9F5; BD), QR-labeled HLA-DR (mIgG2a; clone 
HK14; Sigma-Aldrich) and APC-labeled CD11c (mIgG2b; clone S-HCL-3; 
BD). DCs (lin, CD123, HLA-DR+, CD11c+) were sorted in a FACSAria 
cytometer (BD). DCs were seeded at 100 × 103 cells/well in 200 µl of me-
dium (RPMI supplemented with 2 mM glutamine, 50 U/ml penicillin,   
50 µg/ml streptomycin, 0.1 mM MEM nonessential amino acids, 10 mM 
Hepes buffer, 0.1 mM sodium pyruvate, and 10% of human AB serum). DCs 
were cultured with medium alone or in the presence of 20 ng/ml of TSLP, 
or different tumor derived products. After 48 h, DCs were harvested and 
washed. The stimulated cells were stained for phenotype analysis or co- 
cultured with allogeneic naive CD4+ T cells.
Immunofluorescence. 6-µm-frozen sections from tissues were fixed with 
cold acetone for 5 min. The sections were labeled with 5 µg/ml of anti-
OX40L antibody (mouse IgG1, 8F4), followed by anti–mouse IgG conju-
gated to Texas red (Jackson ImmunoResearch Laboratories). For IL-13, tissue 
was labeled with 10 µg/ml of anti–IL-13 (polyclonal goat IgG; AF-123-NA; 
R&D System) followed with Texas red anti–goat IgG (Jackson Immuno-
Research Laboratories). TSLP was detected with 10 µg/ml of mouse anti-TSLP 
antibody prepared in-house (mIgG1; clone 14C3.2E11). Cytokeratin 19 was 
labeled with monoclonal antibody clone A53-BA2 (IgG2a; Abcam), followed 
by Alexa Fluor 568 goat anti–mouse IgG2a (Invitrogen). The following di-
rect-labeled antibodies used were as follows: FITC anti–HLA-DR (mouse 
IgG2a; L243; BD), FITC anti-CD11c (clone; KB 90; Dako), FITC anti-Ki67 
Our results add another feature to the role of OX40L in 
tumors. Indeed, several studies in mouse models of transplant-
able tumors suggested that engaging OX40 via an agonist anti-
body, OX40L.Fc, or transfected tumor cells and DCs appears 
to promote antitumor effects (Weinberg et al., 2000; Morris 
et al., 2001; Ali et al., 2004; Piconese et al., 2008). However, 
Tnfsf4 (gene coding OX40L) is regulated by the mRNA 
MIRN125B (Smirnov and Cheung, 2008), whose expression 
is down-regulated in breast cancer (Iorio et al., 2005). Tnfsf4 
is up-regulated in ataxia telangiectasia carriers and patients 
(Smirnov and Cheung, 2008), who have been shown to have 
an increased risk of breast cancer (Swift et al., 1987). Further-
more, a recent pilot study described the expression of OX40 
and OX40L in >100 tissue samples from invasive ductal car-
cinomas, and suggested a possible association of OX40 ex-
pression and lymph node metastatic status (Xie et al., 2010). 
OX40L signaling has several important features that might 
help explain the results observed in our and other studies. 
Thus, OX40L triggers Th2 polarization independent of IL-4, 
promotes TNF production, and inhibits IL-10 production by 
the developing Th2 cells, but only in the absence of IL-12. In 
the presence of IL-12, OX40L signaling instead promotes the 
development of Th1 cells that, like inflammatory Th2 cells, 
produce TNF but not IL-10 (Liu et al., 2007).
Interestingly, inflammatory Th2 cells coexist within the 
tumor immune environment alongside IL-10–secreting CD4+ 
T cells. Recent studies demonstrate a colocalization of cells 
with the phenotype of T reg cells) with mature DCs in lym-
phoid infiltrates in breast cancer (Gobert et al., 2009). A high 
number of FoxP3+ T reg cells was associated with disease re-
lapse (Gobert et al., 2009). Thus, the niche finding and metas-
tasis formation might be facilitated by inflammatory Th2 
response, whereas in the established tumor a T reg cell re-
sponse might prevail. Interestingly, CCL22 (a macrophage-
derived chemokine) appears involved in the attraction of   
T reg cells (Gobert et al., 2009), but also, in cooperation with 
CCL17 (TARC), of inflammatory Th2 cells (Liu et al., 2007). 
How this fine balance between T reg cells and Th2 responses 
is regulated will require further study.
Two key questions arise from our work: (1) what are the 
mechanisms allowing TSLP release from cancer cells; and   
(2) what is the impact of IL-13 (and IL-4) on cancer cells, 
on the stroma, and on the immune infiltrate? Our data show   
that nonmalignant breast epithelia can express TSLP. This fur-
ther demonstrates that cancer cells can exploit pathways that 
are present in the normal tissue to establish a microenviron-
ment  facilitating  tumor  development. The  mechanisms 
regulating TSLP expression and secretion from cancer cells, 
including a potential link with oncogenic events, remain to 
be established. It will also be important to determine the   
impact of TSLP and inflammatory Th2 environment on the 
stromal fibroblasts. Indeed, recent studies point to the critical 
role of cross talk between cancer cells and fibroblasts in deter-
mining the type of microenvironment established by cancer 
cells originating from different types of breast cancers (Camp 
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followed by surface and intracellular staining. For blocking OX40L, tumor-
activated mDCs were co-cultured with naive CD4 T cells in the presence of 
50 µg of anti-OX40L (Ik-5 clone) or control IgG2a isotype antibody. For 
blocking TSLP, tumor-derived factors were preincubated with 20 µg/ml of 
anti-TSLP antibody (rabbit; AB 19024) or normal rabbit IgG (R&D Sys-
tems) at room temperature for 30 min after DC activation. DCs were acti-
vated with the neutralized tumor-derived factors and finally co-cultured 
with naive CD4 T cells for 7 d. For TSLPR blocking, DCs were preincubated 
with anti-TSLP receptor antibody (clone AB81_85.1F11; mouse IgG1) for   
3 min at room temperature.
Tumor-bearing mice. Mice were humanized either by CD34+ hemato-
poietic progenitor cell (HPC) transplant or by co-administration of DCs and 
T cells as described previously (Aspord et al., 2007; Institutional Animal Care 
and Use Committee no. A01-005). CD34+HPCs were obtained from apher-
esis of adult healthy volunteers mobilized with G-CSF and purified as de-
scribed previously (Aspord et al., 2007). The CD34 fraction of apheresis was 
Ficoll purified, and the PBMCs obtained were stored frozen and used as a 
source of autologous T cells. 3 million CD34+ HPCs were transplanted intra-
venously into sublethally irradiated (12 cGy/g body weight of 137Cs  irra-
diation)  nonobese  diabetic/LtSz-scid/scid  2  microglobulin–deficient 
(NOD/SCID/2m/) mice (Jackson ImmunoResearch Laboratories).   
After 4 wk of engraftment, 10 million Hs578T breast cancer cells were har-
vested from cultures and injected subcutaneously into the flanks of the mice. 
Mice were reconstituted with 10 million CD4+ T cells and 10 million CD8+ 
T cells autologous to the grafted CD34+ HPCs. CD4+ and CD8+ T cells 
were positively selected from thawed PBMCs using magnetic selection ac-
cording to the manufacturer’s instructions (Miltenyi Biotec). The purity was 
routinely >90%. T cells were transferred at days 3, 6, and 9 after tumor im-
plantation. For experiments with NOD/SCID/2m/ mice, they were 
sublethally irradiated the day before tumor implantation. Mice were then re-
constituted with 1 million monocyte-derived DCs (MDDCs) and autolo-
gous T cells as described in the previous paragraph. MDDCs were generated 
from the adherent fraction of PBMCs by culturing with 100 ng/ml GM-
CSF (Immunex) and 10 ng/ml IL-4 (R&D Systems). Tumor size was moni-
tored every 2–3 d. Tumor volume (ellipsoid) was calculated as follows: ([short 
diameter]2 × long diameter)/2.
Blocking in vivo experiments. For different experimental purposes,   
tumor-bearing mice transferred with autologous T cells were injected intra-
tumorally with 200 µg of anti-OX40L (clone IK-5; mIgG2a) blocking anti-
body, 100 µg of anti-TSLP antibody (clone AB19024; rabbit IgG), 100 µg of 
anti-IL-13 neutralizing antibody prepared in-house (clone 13G1.B2; mIgG1), 
200 µg of anti-TSLPR neutralizing antibody (clone AB81_85.1F11; mouse 
IgG1), or isotype control, respectively at days 3, 6, and 9 after tumor implan-
tation. For blocking TSLP, anti-TSLP antibody injection was also given at day 
0 while the tumor was implanted.
Online supplemental material. Fig. S1 illustrates gating strategy for flow 
cytometry analysis of tumor-infiltrating lymphocytes and the accumulation 
of lymphocytes in tumor beds as compared with surrounding tissue. Fig. S2 
shows that mDCs exposed to TSLP or to soluble tumor factors in the pres-
ence of anti-OX40L are unable to drive the differentiation of inflammatory 
Th2 cells. Fig. S3 shows the specificity of anti-TSLP antibody staining in fro-
zen tissue sections. Fig. S4 shows the expression of TSLP in breast cancer cells 
and in nonmalignant breast tissue. Table S1 provides the pathological diagno-
sis information and Luminex data for cytokine levels of all 99 breast cancer 
patients used for cytokine analysis. Table S2 describes the characteristics of 
breast cancer cell lines studied. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20102131/DC1.
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(clone ki-67; Dako), and Alexa Fluor 488 anti-CD3 (mIgG1; UCHT1; BD). 
Finally, sections were counterstained for 2 min with 3 µM of the nuclear stain 
DAPI (in PBS; Invitrogen). To confirm specificity of TSLP staining, primary 
anti-TSLP antibody was preincubated with 100 µg of recombinant human 
TSLP (R&D Systems) for 30 min at room temperature before staining of   
tissue sections that previously showed to be TSLP positive.
Flow cytometry analysis. Cell suspensions from human breast carcinoma 
tissue and tumor or draining lymph nodes from humanized mice were used 
for phenotypic characterization of leukocytes. Cell suspensions were ob-
tained by digestion with 2.5 mg/ml of collagenase D (Roche), and 200 U/ml 
of DNase I (Sigma-Aldrich) for 30–60 min at 37°C. The anti–human anti-
bodies used were as follows: labeled FITC-labeled lineage cocktail (CD3, 
CD14, CD16, CD19, CD20, and CD56; BD); PE-labeled OX40L (mIgG1; 
clone Ik-1; BD); QR-labeled HLA-DR (mIgG2a; clone HK14; Sigma- 
Aldrich); APC-labeled CD11c (mIgG2b; clone S-HCL-3; BD); PerCP-labeled 
CD3 (mIgG1; clone SK7; BD); PECy7-labeled CD4 (mIgG1; clone SK3; 
BD); APCCy7-labeled CD8 (mIgG1; clone SK1; BD); CFS-labeled IL-4 
(mIgG1; clone 3007; R&D Systems); Pacific blue–labeled IL-10 (rat IgG1; 
clone JES3-9D7; eBioscience); PE-labeled IL-13 (rat IgG1; clone JES10-5A2 
BD); APC-labeled TNF (mIgG1; clone 6401.1111; BD); Alexa Fluor 700– 
labeled IFN- (mIgG1; clone B27; BD). Cells were incubated with the   
antibodies for 30 min at 4°C in the dark, and then washed three times and 
fixed with 1% paraformaldehyde to be analyzed in a FACSCalibur or LSR-II 
cytometer (BD). For intracellular cytokines, cells were stained using BD   
Cytofix/Cytoperm fixation/permeabilization kit according to the manufac-
turer’s directions.
Tumor factors preparation. Tumor factors were obtained from superna-
tant of established breast cancer cell lines cultured in vitro (Table S2; Soule   
et al., 1973; Hackett et al., 1977; Lacroix and Leclercq, 2004; Neve et al., 
2006) or by sonication from tumor cell lines, human breast tumor tissue, or 
tumors from humanized mice. In brief, cell lines were culture in medium 
(RPMI supplemented with 2 mM glutamine, 50 U/ml penicillin, 50 µg/ml 
streptomycin, 0.1 mM MEM nonessential amino acids, 10 mM Hepes buffer, 
0.1 mM sodium pyruvate, and 10% fetal calf serum), and when the cells 
reached 90% of confluence fresh medium was added and the cells were left 
in culture for an additional 48 h. For sonication, cells or tissues were placed 
in PBS and disrupted for 30 s at 4°C, with the power output adjusted at 4.5 
level of the 60 sonic dismembrator (Thermo Fisher Scientific). Cellular de-
bris was removed by centrifugation, and the supernatant was collected and 
stored at 80°C.
Cytokine analysis. Tumor samples from patients diagnosed with breast car-
cinoma (in situ, invasive duct, and/or mucinous carcinoma of the breast, as 
well as lobular carcinoma) were obtained from the Baylor University Medical 
Center Tissue Bank (Institutional Review Board no. 005–145). Tumors and 
draining lymph nodes from mice implanted with breast cancer cell lines 
H578T and MDA-MB-231 were also analyzed. Whole-tissue fragments (4 × 
4 × 4 mm, 0.02 g, approximately) were placed in culture medium with   
50 ng/ml of PMA (Sigma-Aldrich) and 1 µg/ml of ionomycin (Sigma-Aldrich) 
for 16 h. Cytokine production was analyzed in the culture supernatant by 
Luminex. For intracellular staining, cells were resuspended at a concentration 
of 106 cells/ml in medium and activated for 5 h with PMA and ionomycin; 
brefeldin A (GolgiPlug; BD) and monensin (GolgiStop; BD) were added for 
the last 2.5 h.
DC–T cell co-cultures. Total CD4+ T cells were enriched from PBMCs of 
healthy donors using magnetic depletion of other leukocytes (EasySep   
Human  CD4+ T  Cell  Enrichment  kit;  STEMCELL Technologies,  Inc.).   
Naive CD4+ T cells were sorted based on the expression of CD4+ CD27+ and 
CD45RA+. Activated mDCs with medium, TSLP, or tumor-derived factors 
were co-cultured with naive CD4+ T cells at a ratio of 1:5 for 7 d. After that, 
the cells were washed and restimulated for 5 h with 50 ng/ml PMA and   
1 µl/ml ionomycin. Brefeldin A and monensin were added for the last 2.5 h, JEM VOL. 208, March 14, 2011 
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